Erin Tischner, DO
Internal Medicine · Covington, KYNPI 1265768725
Payments from drug & device makers
Across 40 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$74
- AstraZeneca$63
- GSK$60
- Amgen$42
- Novartis$42
- Novo Nordisk$39
- plus $297 from 17 others
What the payments were for
- Food & beverage$617100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $74 |
| AstraZeneca | 4 | $63 |
| GSK | 4 | $60 |
| Amgen | 3 | $42 |
| Novartis | 2 | $42 |
| Novo Nordisk | 3 | $39 |
| Amarin Pharma, Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Qiagen, LLC | 1 | $18 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Mannkind Corporation | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$617 in reported general payments places this provider in the 55th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 31 | $48,223 |
| EliquisApixaban | 29 | $35,227 |
| OzempicSemaglutide | 20 | $29,792 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $29,458 |
| TrulicityDulaglutide | 13 | $21,149 |
| Spiriva RespimatTiotropium Bromide | 17 | $15,000 |
| JanuviaSitagliptin Phosphate | 22 | $14,797 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,227 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $10,267 |
| XareltoRivaroxaban | 12 | $7,145 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,856 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 120 | $3,340 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $2,883 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $2,331 |
| Lubiprostone | 12 | $1,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $74 | $63,22348 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $60 | $45,58160 claims |
| PfizerEliquis | $14 | $35,22729 claims |
| Novo NordiskOzempic | $39 | $29,79220 claims |
| Lilly USA, LLCTrulicity | $12 | $21,14913 claims |
| MerckJanuvia | $11 | $14,79722 claims |
| AstraZenecaBreztri Aerosphere | $63 | $12,22717 claims |
| Johnson & JohnsonXarelto | $12 | $7,14512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Covington
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.